PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) Altman Z2-Score

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:DGNS PT Diagnos Laboratorium Utama Tbk ISX:DGNS
21 GF Score
Price Rp224.00
! 1 Warning Sign
View Full Analysis

What is PT Diagnos Laboratorium Utama Tbk Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

PT Diagnos Laboratorium Utama Tbk does not have enough data to calculate Altman Z2-Score.


PT Diagnos Laboratorium Utama Tbk  (ISX:DGNS) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


PT Diagnos Laboratorium Utama Tbk Altman Z2-Score Related Terms


PT Diagnos Laboratorium Utama Tbk Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for PT Diagnos Laboratorium Utama Tbk's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Diagnos Laboratorium Utama Tbk Altman Z2-Score Chart

PT Diagnos Laboratorium Utama Tbk Annual Data
Trend
Altman Z2-Score

PT Diagnos Laboratorium Utama Tbk Semi-Annual Data
Altman Z2-Score

ISX:DGNS vs TMO, DHR, IDXX: Altman Z2-Score Comparison

For the Diagnostics & Research subindustry, PT Diagnos Laboratorium Utama Tbk's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Diagnos Laboratorium Utama Tbk Altman Z2-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PT Diagnos Laboratorium Utama Tbk's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where PT Diagnos Laboratorium Utama Tbk's Altman Z2-Score falls into.


ISX:DGNS
21GF Score
PT Diagnos Laboratorium Utama Tbk ISX:DGNS
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Diagnos Laboratorium Utama Tbk Business Description

Address Jl. Cikditiro No. 11 A, B, C, Gedung Graha Anam Lantai 2, Kelurahan Gondangdia, Kecamatan Menteng, Jakarta Pusat, Jakarta, IDN, 10350
PT Diagnos Laboratorium Utama Tbk operates in the field of Health Support Services and Private Clinic Activities. It provides health support service activities managed by both the government and the private sector, such as health laboratories in the form of X-Ray Laboratories, and other diagnostic imaging centers, as well as blood testing, private clinics, pharmaceutical warehouses, eye banks, blood banks, sperm banks, organ transplant banks, and other medical support services. Its products and services include Clinical Pathology Laboratory, Anatomical Pathology Laboratory, Genomics Laboratory, Homecare Health Services, Corporate Health Services, Microbiology Laboratory, and Research Services.
21GF Score

Get the complete analysis for ISX:DGNS

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp224.00
Price